Published in J Steroid Biochem Mol Biol on September 07, 2007
Selectively targeting estrogen receptors for cancer treatment. Adv Drug Deliv Rev (2010) 1.02
Identification and characterization of estrogen receptor-related receptor alpha and gamma in human glioma and astrocytoma cells. Mol Cell Endocrinol (2009) 0.89
In vitro evaluation of a tetrahydroisoquinoline derivative as a steroid sulfatase inhibitor and a selective estrogen receptor modulator. Invest New Drugs (2014) 0.75
Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology (1997) 10.08
The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell (1998) 9.96
Phyto-oestrogens and Western diseases. Ann Med (1997) 3.13
Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J (1999) 2.81
Dietary isoflavones: biological effects and relevance to human health. J Nutr (1999) 2.45
Phytoestrogen interaction with estrogen receptors in human breast cancer cells. Endocrinology (1978) 2.42
Flavonoids and isoflavonoids - a gold mine for metabolic engineering. Trends Plant Sci (1999) 1.83
Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res (1989) 1.82
Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res (2000) 1.69
Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene (1999) 1.50
Dietary flavonoids and cancer risk: evidence from human population studies. Nutr Cancer (2004) 1.47
Phyto-oestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br J Nutr (2004) 1.41
Dietary genistein: perinatal mammary cancer prevention, bioavailability and toxicity testing in the rat. Carcinogenesis (1998) 1.38
Growth-inhibitory effects of the natural phyto-oestrogen genistein in MCF-7 human breast cancer cells. Eur J Cancer (1994) 1.32
Enzyme-linked immunosorbent assay (ELISA) for the specific detection of apoptotic cells and its application to rapid drug screening. J Immunol Methods (2001) 1.31
Differential interaction of the methoxychlor metabolite 2,2-bis-(p-hydroxyphenyl)-1,1,1-trichloroethane with estrogen receptors alpha and beta. Endocrinology (1999) 1.29
From chemoprevention to chemotherapy: common targets and common goals. Expert Opin Investig Drugs (2004) 1.22
Genistein inhibition of the growth of human breast cancer cells: independence from estrogen receptors and the multi-drug resistance gene. Biochem Biophys Res Commun (1991) 1.13
Understanding the selectivity of genistein for human estrogen receptor-beta using X-ray crystallography and computational methods. Structure (2004) 1.10
Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator. J Med Chem (1997) 1.07
Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells. Cell Growth Differ (1996) 1.06
Chemopreventive effects of soy protein and purified soy isoflavones on DMBA-induced mammary tumors in female Sprague-Dawley rats. Nutr Cancer (2001) 1.04
Soybeans inhibit mammary tumors in models of breast cancer. Prog Clin Biol Res (1990) 0.99
Estrogenic flavonoids: structural requirements for biological activity. Proc Soc Exp Biol Med (1995) 0.97
Soy extract inhibits mammary adenocarcinoma growth in a syngeneic mouse model. Cancer Lett (2003) 0.90
Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators. J Med Chem (1998) 0.89
Dietary fiber, phytoestrogens, and breast cancer. Nutrition (1992) 0.85
Molecular identification of potential selective estrogen receptor modulator (SERM) like properties of phytoestrogens in the human breast cancer cell line MCF-7. Planta Med (2001) 0.85
Synthesis and estrogen receptor binding affinities of 7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-ones containing a basic side chain. Bioorg Med Chem Lett (2003) 0.83
Pleotropic effects of genistein on MCF-7 breast cancer cells. Int J Mol Med (2003) 0.82
Synthesis and aromatase inhibitory activity of novel pyridine-containing isoflavones. J Med Chem (2004) 0.80
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet (2012) 6.83
Association of family history with cancer recurrence and survival in patients with gastric cancer. J Clin Oncol (2012) 2.97
Surgical complications and the risk factors of laparoscopy-assisted distal gastrectomy in early gastric cancer. Ann Surg Oncol (2008) 2.10
Prognostic value of preoperative clinical staging assessed by computed tomography in resectable gastric cancer patients: a viewpoint in the era of preoperative treatment. Ann Surg (2010) 1.84
Endoscopic submucosal dissection for metachronous tumor in the remnant stomach after distal gastrectomy. Surg Endosc (2009) 1.63
Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab (2005) 1.56
Oncologic effectiveness of regular follow-up to detect recurrence after curative resection of gastric cancer. Ann Surg Oncol (2010) 1.54
Developing an institutional protocol guideline for laparoscopy-assisted distal gastrectomy. Ann Surg Oncol (2009) 1.51
Covered versus uncovered self-expandable metallic stents for palliation of malignant pyloric obstruction in gastric cancer patients: a randomized, prospective study. Gastrointest Endosc (2010) 1.51
Effect of repeated endoscopic screening on the incidence and treatment of gastric cancer in health screenees. Eur J Gastroenterol Hepatol (2009) 1.51
Reconsidering the length of program accreditation. Am J Pharm Educ (2011) 1.44
Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer. Eur J Nucl Med Mol Imaging (2005) 1.42
Technical feasibility and safety of laparoscopy-assisted total gastrectomy in gastric cancer: a comparative study with laparoscopy-assisted distal gastrectomy. J Surg Oncol (2009) 1.41
Optimal submucosal invasion of early gastric cancer for endoscopic resection. Ann Surg Oncol (2015) 1.39
Web-based tailored education program for disease-free cancer survivors with cancer-related fatigue: a randomized controlled trial. J Clin Oncol (2012) 1.34
Is the T9, T11, or L1 the more reliable proximal level after adult lumbar or lumbosacral instrumented fusion to L5 or S1? Spine (Phila Pa 1976) (2007) 1.30
Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J Clin Oncol (2004) 1.22
Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition. J Med Chem (2006) 1.19
Is the sentinel node biopsy clinically applicable for limited lymphadenectomy and modified gastric resection in gastric cancer? A meta-analysis of feasibility studies. J Surg Oncol (2011) 1.18
A functional single nucleotide polymorphism in mucin 1, at chromosome 1q22, determines susceptibility to diffuse-type gastric cancer. Gastroenterology (2010) 1.17
Estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer. Carcinogenesis (2003) 1.16
Robot-assisted total gastrectomy is comparable with laparoscopically assisted total gastrectomy for early gastric cancer. Surg Endosc (2011) 1.16
Preferences for and experiences of family involvement in cancer treatment decision-making: patient-caregiver dyads study. Psychooncology (2013) 1.15
Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor. Mol Cancer Ther (2008) 1.15
Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Mol Pharmacol (2005) 1.13
Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes. J Clin Endocrinol Metab (2003) 1.12
Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Mol Pharmacol (2006) 1.12
Survival and surgical outcomes after laparoscopy-assisted total gastrectomy for gastric cancer: case-control study. Surg Endosc (2012) 1.12
The risk factors for lymph node metastasis in early gastric cancer patients who underwent endoscopic resection: is the minimal lymph node dissection applicable? A retrospective study. Surg Endosc (2013) 1.12
Is the new seventh AJCC/UICC staging system appropriate for patients with gastric cancer? J Am Coll Surg (2011) 1.11
Sentinel node mapping and skip metastases in patients with early gastric cancer. Ann Surg Oncol (2009) 1.11
Learning curve for total gastrectomy with D2 lymph node dissection: cumulative sum analysis for qualified surgery. Ann Surg Oncol (2006) 1.10
The final catalytic step of cytochrome p450 aromatase: a density functional theory study. J Am Chem Soc (2005) 1.08
Association of the interval between endoscopies with gastric cancer stage at diagnosis in a region of high prevalence. Cancer (2012) 1.07
Genomic profile analysis of diffuse-type gastric cancers. Genome Biol (2014) 1.07
ALU and LINE-1 hypomethylations in multistep gastric carcinogenesis and their prognostic implications. Int J Cancer (2012) 1.07
Health-related quality of life among disease-free stomach cancer survivors in Korea. Qual Life Res (2006) 1.06
Multicenter Prospective Comparative Study of Robotic Versus Laparoscopic Gastrectomy for Gastric Adenocarcinoma. Ann Surg (2016) 1.05
Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells. J Steroid Biochem Mol Biol (2002) 1.05
Clinical characteristics and treatment outcomes of gastric cancer patients with isolated para-aortic lymph node involvement. Cancer Chemother Pharmacol (2010) 1.04
The association between Helicobacter pylori status and incidence of metachronous gastric cancer after endoscopic resection of early gastric cancer. Helicobacter (2014) 1.04
Knowledge, attitudes, risk perception, and cancer screening behaviors among cancer survivors. Cancer (2011) 1.01
Endoscopic ultrasound and computed tomography in restaging and predicting prognosis after neoadjuvant chemotherapy in patients with locally advanced gastric cancer. Cancer (2008) 1.00
Are we producing innovators and leaders or change resisters and followers? Am J Pharm Educ (2012) 1.00
Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. Int J Radiat Oncol Biol Phys (2012) 1.00
Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer. J Steroid Biochem Mol Biol (2005) 0.99
Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer. Anticancer Agents Med Chem (2006) 0.99
Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist (2008) 0.99
A phase-II clinical trial of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for gastric cancer patients. Ann Surg Oncol (2007) 0.99
Comparison of radiographic outcomes for the treatment of scoliotic curves greater than 100 degrees: wires versus hooks versus screws. Spine (Phila Pa 1976) (2008) 0.99
Laparoscopic wedge resection with handsewn closure for gastroduodenal tumors. J Laparoendosc Adv Surg Tech A (2003) 0.98
Predictors of timing and patterns of recurrence after curative resection for gastric cancer. Dig Surg (2010) 0.98
Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7alpha-APTADD to breast cancer cells. Int J Pharm (2010) 0.97
Laparoscopy-assisted D2 subtotal gastrectomy in early gastric cancer. Surg Laparosc Endosc Percutan Tech (2003) 0.97
Effects of interleukin-10 polymorphisms, Helicobacter pylori infection, and smoking on the risk of noncardia gastric cancer. PLoS One (2012) 0.97
Intravascular ultrasonography-guided stent angioplasty of an extracranial vertebral artery dissection. J Neurosurg (2008) 0.96
The influence of reconstruction methods on food retention phenomenon in the remnant stomach after a subtotal gastrectomy. J Surg Oncol (2008) 0.96
Aromatase and COX in breast cancer: enzyme inhibitors and beyond. J Steroid Biochem Mol Biol (2007) 0.94
Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer. Pharmacogenomics (2009) 0.94
Preoperative plasma fibrinogen level is a useful predictor of adjacent organ involvement in patients with advanced gastric cancer. J Gastric Cancer (2012) 0.93
Synthesis and biological evaluation of novel sulfonanilide compounds as antiproliferative agents for breast cancer. J Comb Chem (2008) 0.93
Altered AIB1 or AIB1Δ3 expression impacts ERα effects on mammary gland stromal and epithelial content. Mol Endocrinol (2011) 0.92
Comparison of increased aromatase versus ERα in the generation of mammary hyperplasia and cancer. Cancer Res (2011) 0.92
Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol (2005) 0.92
Health-related quality of life after robot-assisted distal gastrectomy in early gastric cancer. World J Surg (2014) 0.92
Outcome of endoscopic therapy for cancer bleeding in patients with unresectable gastric cancer. J Gastroenterol Hepatol (2013) 0.91
Stitched α-helical peptides via bis ring-closing metathesis. J Am Chem Soc (2014) 0.90
Synthesis and biological evaluation of selective aromatase expression regulators in breast cancer cells. J Med Chem (2007) 0.90
Self-expandable metallic stent placement for malignant obstruction in patients with locally recurrent gastric cancer. Surg Endosc (2010) 0.89
The morbidity of an anterior thoracolumbar approach: adult spinal deformity patients with greater than five-year follow-up. Spine (Phila Pa 1976) (2009) 0.89
SPANosomes as delivery vehicles for small interfering RNA (siRNA). Mol Pharm (2011) 0.88
Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay. J Nat Prod (2006) 0.88
Increased proteasome-dependent degradation of estrogen receptor-alpha by TGF-beta1 in breast cancer cell lines. J Cell Biochem (2003) 0.88
Construction of an integration-proficient vector based on the site-specific recombination mechanism of enterococcal temperate phage phiFC1. J Bacteriol (2002) 0.88
Changing pattern of postoperative body weight and its association with recurrence and survival after curative resection for gastric cancer. Hepatogastroenterology (2012) 0.87
Xanthones from the botanical dietary supplement mangosteen (Garcinia mangostana) with aromatase inhibitory activity. J Nat Prod (2008) 0.87
Risk of lymph node metastasis in differentiated type mucosal early gastric cancer mixed with minor undifferentiated type histology. Ann Surg Oncol (2014) 0.87
Prospective Multicenter Feasibility Study of Laparoscopic Sentinel Basin Dissection for Organ Preserving Surgery in Gastric Cancer: Quality Control Study for Surgical Standardization Prior to Phase III Trial. Medicine (Baltimore) (2015) 0.86
Proposal of the surgical options for primary tumor control during sentinel node navigation surgery based on the discrepancy between preoperative and postoperative early gastric cancer diagnoses. Ann Surg Oncol (2013) 0.86
Biopsy site for detecting Helicobacter pylori infection in patients with gastric cancer. J Gastroenterol Hepatol (2009) 0.85
Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition. Steroids (2007) 0.85
Argon plasma coagulation is safe and effective for treating smaller gastric lesions with low-grade dysplasia: a comparison with endoscopic submucosal dissection. Surg Endosc (2012) 0.85
Characteristics of gastric cancer according to Helicobacter pylori infection status. J Gastroenterol Hepatol (2014) 0.85
Recapitulation of previous genome-wide association studies with two distinct pathophysiological entities of gastric cancer in the Korean population. J Hum Genet (2013) 0.85
Mechanisms of Nrf2/Keap1-dependent phase II cytoprotective and detoxifying gene expression and potential cellular targets of chemopreventive isothiocyanates. Oxid Med Cell Longev (2013) 0.85
Effective diameter of balloon dilation for benign esophagojejunal anastomotic stricture after total gastrectomy. Surg Endosc (2008) 0.84
Association of smoking history with cancer recurrence and survival in stage III-IV male gastric cancer patients. Cancer Epidemiol Biomarkers Prev (2013) 0.84
Increasing the DNA damage threshold in breast cancer cells. Toxicol Appl Pharmacol (2002) 0.84
Preoperative versus postoperative Helicobacter pylori eradication therapy in gastric cancer patients: a randomized trial. Am J Gastroenterol (2007) 0.84
Risk factors associated with gastric cancer in patients with a duodenal ulcer. Helicobacter (2010) 0.84
Novel sulfonanilide analogs decrease aromatase activity in breast cancer cells: synthesis, biological evaluation, and ligand-based pharmacophore identification. J Med Chem (2008) 0.84
Preoperative serum angiopoietin-2 levels correlate with lymph node status in patients with early gastric cancer. Ann Surg Oncol (2009) 0.84
Human serum albumin-coated lipid nanoparticles for delivery of siRNA to breast cancer. Nanomedicine (2012) 0.83
Laparoscopy Assisted versus Open Distal Gastrectomy with D2 Lymph Node Dissection for Advanced Gastric Cancer: Design and Rationale of a Phase II Randomized Controlled Multicenter Trial (COACT 1001). J Gastric Cancer (2013) 0.83
Synthesis and estrogen receptor binding affinities of 7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-ones containing a basic side chain. Bioorg Med Chem Lett (2003) 0.83